Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

NCT05864534 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed Glioblastoma
Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype
Gliosarcoma
Glioblastoma Multiforme

Interventions

DRUG: Balstilimab
DRUG: Botensilimab
DRUG: Liposomal Doxorubicin
DEVICE: Sonocloud-9 (SC-9)

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]